Abbott was Pfizer's mystery competitor in bid for Wyeth; WSJ

The USA's Abbott Laboratories was Pfizer's mysterious competitior in its bid to acquire Wyeth, reports the Wall Street Journal. Pfizer had  written in Securities and Exchange documents that there had been another  possible suitor for Wyeth and the WSJ now suggests that Abbott held  talks on the acquisition in December. However, the newspaper quotes an  anonymous source who maintains that Abbott was only willing to offer  around $45 per share and could not compete with Pfizer's $50.19 offer,  feeling that a mega-merger of that magnitude would negatively affect its  own share price. Nonetheless, the WSJ notes this may suggest Abbott is  open to other large acquisitions in the future.